blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2805729

EP2805729 - ANTI-HBC QUANTITATIVE DETECTION IN PREDICTING THERAPEUTIC EFFECT OF CHRONIC HEPATITIS B PATIENT [Right-click to bookmark this link]
Former [2014/48]ANTI-HBC QUANTITATIVE DETECTION METHOD AND USES THEREOF IN MONITORING AND CONTROLLING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENT AND IN PREDICTING THERAPEUTIC EFFECT
[2018/29]
StatusNo opposition filed within time limit
Status updated on  15.11.2019
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  07.12.2018
FormerGrant of patent is intended
Status updated on  16.07.2018
FormerExamination is in progress
Status updated on  01.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Xiamen University
No. 422, Siming Nan Road
Siming District
Xiamen, Fujian 361005 / CN
For all designated states
Xiamen Innovax Biotech Co., Ltd.
130 Xinyuan Road
Haicang
Xiamen, Fujian 361022 / CN
[2014/48]
Inventor(s)01 / YUAN, Quan
Xiang'an Campus Of Xiamen University
Xiang'an South Road
Xiang'an District
Xiamen Fujian 361104 / CN
02 / SONG, Liuwei
Xiang'an Campus Of Xiamen University
Xiang'an South Road
Xiang'an District
Xiamen Fujian 361104 / CN
03 / ZHOU, Wenbin
No. 130 Xinyuan Road
Haicang District
Xiamen Fujian 361022 / CN
04 / WENG, Zuxing
No. 130 Xinyuan Road
Haicang District
Xiamen Fujian 361022 / CN
05 / XU, Feihai
No. 130 Xinyuan Road
Haicang District
Xiamen Fujian 361022 / CN
06 / GE, Shengxiang
Xiang'an Campus Of Xiamen University
Xiang'an South Road
Xiang'an District
Xiamen Fujian 361104 / CN
07 / ZHANG, Jun
Xiang'an Campus Of Xiamen University
Xiang'an South Road
Xiang'an District
Xiamen Fujian 361104 / CN
08 / XIA, Ningshao
Xiang'an Campus Of Xiamen University
Xiang'an South Road
Xiang'an District
Xiamen Fujian 361104 / CN
 [2014/48]
Representative(s)Held, Stephan
Meissner Bolte Patentanwälte
Rechtsanwälte Partnerschaft mbB
Widenmayerstraße 47
80538 München / DE
[2019/02]
Former [2014/48]Held, Stephan
Meissner, Bolte & Partner GbR
Widenmayerstraße 47
80538 München / DE
Application number, filing date13738450.917.01.2013
[2019/02]
WO2013CN70573
Priority number, dateCN2012101938921.01.2012         Original published format: CN201210019389
[2014/48]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013107355
Date:25.07.2013
Language:ZH
[2013/30]
Type: A1 Application with search report 
No.:EP2805729
Date:26.11.2014
Language:EN
[2014/48]
Type: B1 Patent specification 
No.:EP2805729
Date:09.01.2019
Language:EN
[2019/02]
Search report(s)International search report - published on:CN25.07.2013
(Supplementary) European search report - dispatched on:EP09.10.2015
ClassificationIPC:G01N33/569, G01N33/576
[2018/29]
CPC:
G01N33/56983 (EP,US); G01N33/5088 (KR); A01K67/0275 (KR);
A61K39/29 (KR); A61P1/16 (EP); A61P31/12 (EP);
A61P43/00 (EP); G01N33/5014 (KR); G01N33/5762 (EP,US);
A01K2217/052 (KR); A01K2227/40 (KR); A01K2267/0393 (KR);
G01N2333/02 (EP,US); G01N2469/20 (EP,US); G01N2800/52 (EP,US);
G01N2800/56 (EP,US) (-)
Former IPC [2015/46]A61K39/29, A61P1/16, G01N33/576, G01N33/569
Former IPC [2015/28]A61K39/29, A61P1/16, G01N33/576
Former IPC [2014/48]A61K39/29, A61P1/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/48]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:QUANTITATIVER NACHWEIS VON ANTI-HBC ZUR VORHERSAGE EINER THERAPEUTISCHEN WIRKUNG BEI PATIENTEN MIT CHRONISCHER HEPATITIS B[2018/29]
English:ANTI-HBC QUANTITATIVE DETECTION IN PREDICTING THERAPEUTIC EFFECT OF CHRONIC HEPATITIS B PATIENT[2018/29]
French:DÉTECTION QUANTITATIVE ANTI-HBC POUR EN PRÉDIRE UN EFFET THÉRAPEUTIQUE CHEZ UN PATIENT ATTEINT DE L'HÉPATITE B CHRONIQUE[2018/29]
Former [2014/48]VERFAHREN ZUM QUANTITATIVEN NACHWEIS VON ANTI-HBC UND ANWENDUNGEN DAVON BEI DER ÜBERWACHUNG UND REGELUNG DES KRANKHEITSVERLAUFS VON PATIENTEN MIT CHRONISCHER HEPATITIS B UND BEI DER VORHERSAGE EINER THERAPEUTISCHEN WIRKUNG
Former [2014/48]ANTI-HBC QUANTITATIVE DETECTION METHOD AND USES THEREOF IN MONITORING AND CONTROLLING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENT AND IN PREDICTING THERAPEUTIC EFFECT
Former [2014/48]PROCÉDÉ DE DÉTECTION QUANTITATIVE ANTI-HBC ET UTILISATIONS DE CELUI-CI POUR LA SURVEILLANCE ET LE CONTRÔLE DE LA PROGRESSION DE LA MALADIE CHEZ UN PATIENT ATTEINT DE L'HÉPATITE B CHRONIQUE ET POUR EN PRÉDIRE UN EFFET THÉRAPEUTIQUE
Entry into regional phase07.08.2014Translation filed 
07.08.2014National basic fee paid 
07.08.2014Search fee paid 
07.08.2014Designation fee(s) paid 
07.08.2014Examination fee paid 
Examination procedure07.08.2014Examination requested  [2014/48]
27.04.2016Amendment by applicant (claims and/or description)
29.09.2016Despatch of a communication from the examining division (Time limit: M04)
31.01.2017Reply to a communication from the examining division
02.11.2017Despatch of a communication from the examining division (Time limit: M04)
14.02.2018Reply to a communication from the examining division
17.07.2018Communication of intention to grant the patent
27.11.2018Fee for grant paid
27.11.2018Fee for publishing/printing paid
27.11.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.09.2016
Opposition(s)10.10.2019No opposition filed within time limit [2019/51]
Fees paidRenewal fee
07.01.2015Renewal fee patent year 03
29.01.2016Renewal fee patent year 04
30.01.2017Renewal fee patent year 05
30.01.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.01.2013
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
MK09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE17.01.2019
LU17.01.2019
MT17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
[2022/31]
Former [2021/32]HU17.01.2013
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE17.01.2019
LU17.01.2019
MT17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2021/26]AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE17.01.2019
LU17.01.2019
MT17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/29]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE17.01.2019
LU17.01.2019
MT17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/17]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
IE17.01.2019
LU17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/13]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
IE17.01.2019
LU17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/09]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
SM09.01.2019
IE17.01.2019
LU17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/51]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
SM09.01.2019
LU17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/50]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
LU17.01.2019
BE31.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/49]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
LU17.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/48]AT09.01.2019
DK09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
LU17.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/46]AT09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
LU17.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/44]FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
LU17.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/39]FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/38]FI09.01.2019
LT09.01.2019
PL09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/37]FI09.01.2019
LT09.01.2019
PL09.01.2019
SE09.01.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/35]FI09.01.2019
LT09.01.2019
PL09.01.2019
SE09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/34]FI09.01.2019
LT09.01.2019
SE09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/33]FI09.01.2019
LT09.01.2019
NO09.04.2019
PT09.05.2019
Documents cited:Search[XA]  - COLLOREDO MELS G ET AL, "Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations.", ARCHIVES OF VIROLOGY, (1993), vol. Suppl. 8, ISSN 0939-1983, pages 203 - 211, XP009184368 [X] 1,2,7,9,10 * the whole document, in particular abstract; paragraph spanning pages 204 and 205; page 209, lines 4-7, 14-21; figure 2 * [A] 3,4
 [XAI]  - Maurizia Rossana Brunetto ET AL, "Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc", Journal of Hepatology, DENMARK, doi:10.1016/S0168-8278(05)80554-9, (19930101), pages 431 - 436, URL: http://www.sciencedirect.com/science/article/pii/S0168827805805549, XP055190278 [X] 1,2,5,7,9,10 * the whole document, in particular title; abstract; page 435, column 2, lines 36-40; figures 2 and 3 * [A] 3,4 [I] 8

DOI:   http://dx.doi.org/10.1016/S0168-8278(05)80554-9
 [XA]  - G COLLOREDO ET AL, "Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B", JOURNAL OF VIRAL HEPATITIS, (19990101), vol. 6, pages 429 - 434, XP055190211 [X] 10 * the whole document, in particular title; abstract; page 432, lines 21-26; page 433, last paragraph; figure 1 * [A] 3,4

DOI:   http://dx.doi.org/10.1046/j.1365-2893.1999.00171.x
 [XAI]  - CLAUDIO GALLI ET AL, "What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?", JOURNAL OF MEDICAL VIROLOGY, (20080101), vol. 80, no. 6, doi:10.1002/jmv.21179, ISSN 0146-6615, pages 974 - 979, XP055190416 [X] 1,2,5,7,9,10 * the whole document, in particular abstract; page 975, column 1, lines 29-41; paragraph spanning pages 975 and 976; page 978, column 1, lines 33-47; figure 3 * [A] 3,4 [I] 8

DOI:   http://dx.doi.org/10.1002/jmv.21179
 [XA]  - YANAN HAN ET AL, "The novel use of a routine quantitative system to analyze the activity, content and affinity of an antibody to hepatitis B core antigen", JOURNAL OF CLINICAL VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 52, no. 4, doi:10.1016/J.JCV.2011.09.002, ISSN 1386-6532, (20110905), pages 295 - 299, (20110909), XP028110603 [X] 1,2,7,9,10 * the whole document, in particular title; abstract; page 298, column 2, lines 37-52 * [A] 3,4

DOI:   http://dx.doi.org/10.1016/j.jcv.2011.09.002
 [XYI]  - GEORGE MARINOS ET AL, "Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection", HEPATOLOGY, (19940201), vol. 19, no. 2, doi:10.1002/hep.1840190207, ISSN 0270-9139, pages 303 - 311, XP055190367 [X] 1,2,5,6 * the whole document, in particular title; abstract; page 305, column 1; figures 3,5; table 2 * [Y] 3,4,8 [I] 8

DOI:   http://dx.doi.org/10.1002/hep.1840190207
 [XAY]  - J-J. CHEN ET AL, "Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, (20060101), vol. 23, no. 1, doi:10.1111/j.1365-2036.2006.02718.x, ISSN 0269-2813, pages 85 - 90, XP055216655 [X] 1,2,5 * the whole document, in particular abstract; page 87, column 1, line 10 to column 2, line 4; page 88, column 2, lines 27-35; page 89, column 2, lines 3-7 * [A] 6 [Y] 3,4,8

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2006.02718.x
International search[A]CN1694898  (ADVANCED LIFE SCIENCE INST INC [JP]);
 [A]CN1908666  (UNIV WUHAN [CN]);
 [X]CN101545906  (BEIJING KE MEI DONG YA BIOLOGY);
 [Y]CN101726596  (WUXI ZODOLABS BIO TECHNOLOGY C);
 [X]  - RODELLA, A. ET AL., "Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B", JOURNAL OF CLINICAL VIROLOGY, (2006), vol. 37, pages 206 - 212, XP028037963

DOI:   http://dx.doi.org/10.1016/j.jcv.2006.06.011
Examination   - R. T. Horvat, G. E. Tegtmeier, "Hepatitis B and D viruses", R. T. Horvat, G. E. Tegtmeier, P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, M. A. Pfaller, Manual of clinical microbiology, 9th edition, Washington, DC, ASM Press, (2007), vol. 2, pages 1641 - 1659
    - Anna S. F. Lok, Francesco Negro, "Chapter 24: Hepatitis B and D", Anna S. F. Lok, Francesco Negro, Eugene R. Schiff, Willis C. Maddrey, Michael F. Sorrell, Schiff's Diseases of the Liver, Eleventh Edition, Wiley, (20111031), pages 537 - 581, ISBN 9780470654682
    - MORBIDITY AND MORTALITY WEEKLY REPORT, (20051223), vol. 54, no. RR-16
    - KALUS U, WILKEMEYER I, CASPARI G, SCHROETER J, PRUSS A, "Validation of the Serological Testing for Anti-HIV-1/2, Anti-HCV, HBsAg, and Anti-HBc from Post-mortem Blood on the Siemens-BEP-III Automatic System", TRANSFUS MED HEMOTHER, (20111117), vol. 38, no. 6, pages 365 - 372
    - "WHO International Standard; First International Standard for anti-Hepatitis B core antigen (anti-HBc), plasma, human; NIBSC code 95/522; Instructions for use; Version 2.0", (20130415), URL: www.google.com
    - LAI M C ET AL, "Is anti-HBc IgM a useful clinical test in patients with HBsAg-positive chronic hepatitis or primary hepatocellular carcinoma?", HEPATOLOGY (BALTIMORE, MD.) 1988 MAY-JUN, (198805), vol. 8, no. 3, ISSN 0270-9139, pages 514 - 517
by applicant   - DIENSTAG JL., "Hepatitis B virus infection", N ENGL J MED, (2008), vol. 359, doi:doi:10.1056/NEJMra0801644, pages 1486 - 1500, XP009184344

DOI:   http://dx.doi.org/10.1056/NEJMra0801644
    - LIAW YF; CHU CM., "Hepatitis B virus infection", LANCET, (2009), vol. 373, doi:doi:10.1016/S0140-6736(09)60207-5, pages 582 - 592, XP025951921

DOI:   http://dx.doi.org/10.1016/S0140-6736(09)60207-5
    - KWON H; LOK AS., "Hepatitis B therapy", NAT REV GASTROENTEROL HEPATOL, (2011), vol. 8, pages 275 - 284
    - DENG LJ; XU Y; HUANG J., "Developing a double-antigen sandwich ELISA for effective detection of human hepatitis B core antibody", COMP IMMUNOL MICROBIOL INFECT DIS, (2008), vol. 31, doi:doi:10.1016/j.cimid.2007.09.001, pages 515 - 526, XP025673831

DOI:   http://dx.doi.org/10.1016/j.cimid.2007.09.001
    - LI A; YUAN Q; HUANG Z; FAN J; GUO R; LOU B ET AL., "Novel double-antigen sandwich immunoassay for human hepatitis B core antibody", CLIN VACCINE IMMUNOL, (2010), vol. 17, doi:doi:10.1128/CVI.00457-09, pages 464 - 469, XP055190201

DOI:   http://dx.doi.org/10.1128/CVI.00457-09
    - ZLOTNICK A; JOHNSON JM; WINGFIELD PW; STAHL SJ; ENDRES D., "A theoretical model successfully identifies features of hepatitis B virus capsid assembly", BIOCHEMISTRY, (1999), vol. 38, pages 14644 - 14652
    - WHO INTERNATIONAL STANDARD: FIRST INTERNATIONAL STANDARD FOR ANTI-HEPATITIS B CORE ANTIGEN, (20081110), URL: www.nibsc.ac.uk/documents/ ifu/95-522.pdf
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.